Streetbeat News

Products Services

FVRR

Fiverr International Ltd. (NYSE:FVRR) has announced major product releases, continuing its tradition of product innovation. The releases follow recent launches including Fiverr Enterprise, Fiverr Certified, and partnerships with brands like Amazon Ads and Stripe. The company is accelerating its investment in moving upmarket and tackling technological challenges to create innovative products.

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 1:08 pm

IMMP

Immutep Limited has received positive scientific advice from the European Medicines Agency (EMA) for the continued development of eftilagimod alpha (efti), the company's soluble LAG-3 protein and first-in-class MHC Class II agonist. The EMA advised that further toxicology studies are not needed for a future Marketing Authorisation Application (MAA). Similar advice was received from the US Food and Drug Administration (FDA). Immutep continues to interact with regulatory agencies regarding its expanding late-stage clinical pipeline with efti.

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 1:05 pm

WKSP

Worksport Ltd. (NASDAQ:WKSP) has announced the early commencement of production in its new 220,000 square-foot West Seneca, NY, facility, a week ahead of schedule. The company's CEO, Steven Rossi, expressed excitement over the development, stating that it represents a major milestone and underlines the company's capabilities in advanced project management and operational efficiency. The early start is expected to boost investor confidence in the company's growth and revenue prospects.

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 1:03 pm

GOOG

GOOGL

GRFS

Grifols, a global healthcare company, has announced a collaboration with Google Cloud to apply artificial intelligence (AI) technologies to accelerate the development of new biopharma medicines. The AI will be used across the drug-development life cycle, including identifying potential therapeutic candidates and managing clinical trial programs. Grifols will also explore new applications and use cases for data and AI in the biopharma sector.

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 1:01 pm

VCYT

Veracyte, Inc. (NASDAQ:VCYT) has published a study demonstrating the effectiveness of its Decipher Prostate Genomic Classifier in guiding personalized treatment for prostate cancer. The study used data from the National Cancer Institute's SEER database and showed that the Decipher test can accurately predict the likelihood of a patient's cancer metastasizing within the next five years. This information can help physicians recommend tailored treatment plans.

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 12:59 pm

MOBQ

Mobiquity Technologies, Inc. (NASDAQ:MOBQ) and Optical Near ME have announced the rollout of their joint marketing program for the eye care industry. The program, which includes innovative shared revenue models and tools for robust data visualization, aims to revolutionize modern optical dispensing and help local optical retail businesses regain their strength. The collaboration targets the $76 billion-dollar industry, with marketing packages starting as low as $3,000/month.

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 12:55 pm

SCPH

scPharmaceuticals Inc. (NASDAQ:SCPH) has received positive feedback from the FDA regarding the potential expansion of the FUROSCIX® indication for use in NYHA Class IV heart failure patients. The company plans to file for Class IV indication expansion by the end of this year. Additionally, the company announced the issuance of U.S. patents covering concentrated formulations of furosemide, enabling the development of additional furosemide formulations for subcutaneous administration.

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 12:50 pm

COEP

Coeptis Therapeutics has filed an FDA 513(g) submission for a CD38 in vitro companion diagnostic. This is a significant step in the development and potential approval of the diagnostic tool.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2023 | 12:49 pm

TYRA

Tyra Biosciences, Inc. (NASDAQ:TYRA) has received FDA Orphan Drug Designation for its lead precision medicine program, TYRA-300, for the treatment of achondroplasia. The company also announced the appointment of Michael Bober, M.D. Ph.D., as Vice President, Clinical Development and Medical Affairs, to lead the skeletal dysplasia program. TYRA-300 is currently being evaluated in a Phase 1/2 clinical study and the company plans to submit an IND for a Phase 2 clinical study in pediatric achondroplasia in 2024.

Portfolio Pulse from Happy Mohamed

August 01, 2023 | 12:47 pm

CRL

Charles River Laboratories (CRL) is expanding its AAALAC-accredited, turnkey research space in Seattle and Philadelphia. The new CRADL spaces will provide flexible vivarium space for the biopharmaceutical industry.

Portfolio Pulse from Benzinga Newsdesk

August 01, 2023 | 12:45 pm